Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Anti-angiogenesis Agent AG-013736 in Patients with Metastatic Melanoma
This study is not yet open for patient recruitment.
Sponsored by: | Pfizer |
---|---|
Information provided by: | Pfizer |
Purpose
This is a Phase 2 study being conducted at multiple centers in the United States. Patients having melanoma that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have disease that has been treated with no more than 1 prior treatment for metastatic disease (prior adjuvant treatment for localized disease does not count as prior treatment for metastatic disease). The purpose of the study is to test whether the angiogenesis inhibitor AG-013736 is an effective treatment for metastatic melanoma as shown by the number of patients in the study who experience significant and durable tumor shrinkage.
Condition | Treatment or Intervention | Phase |
---|---|---|
Melanoma Metastases |
Drug: AG-013736 |
Phase II |
MedlinePlus related topics: Cancer; Cancer Alternative Therapy; Melanoma
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: Phase 2 Study of the Anti-angiogenesis Agent AG-013736 in Patients with Metastatic Melanoma
Expected Total Enrollment: 60
Study start: November 2004
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Major entry criteria include the following:
Location Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |